E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer |
|
E.1.1.1 | Medical condition in easily understood language |
Specific type of lung cancer called “Non-Small Cell Lung Cancer” |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10029514 |
E.1.2 | Term | Non-small cell lung cancer NOS |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of durvalumab with SoC SBRT compared to placebo with SoC SBRT in terms of PFS in patients with subset of T1-T3N0 NSCLC. |
|
E.2.2 | Secondary objectives of the trial |
To assess the efficacy of durvalumab with SBRT compared to placebo with SBRT in terms of PFS for all stage I/II NSCLC patients.To assess the efficacy of durvalumab with SBRT compared to placebo with SBRT in terms of OS in patients with subset of T1-T3N0 NSCLC.To assess the efficacy of durvalumab with SBRT compared to placebo with SBRT in terms of OS in patients with Stage I/II NSCLC.To further assess the efficacy of durvalumab with SBRT compared to placebo with SBRT in terms of lung cancer-specific mortality.To further assess the efficacy of durvalumab with SBRT compared to placebo with SBRT in terms of PFS24, TTP, TTDM, PFS2.To assess the PK of durvalumab.To investigate the immunogenicity of durvalumab.To assess symptoms and health-related quality of life in patients treated with durvalumab with SBRT compared to placebo with SBRT using the EORTC QLQ-C30.To assess the safety and tolerability profile of durvalumab with SBRT compared to placebo with SBRT |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Age ≥18 years
2. Histologically or cytologically documented Stage I to II NSCLC, with clinical Stage I/II lymph node-negative (T1 to T3N0M0) disease and planned to receive definitive treatment with SBRT. Patients may be medically inoperable or are medically operable and refusing surgery or choosing to have SBRT (Stereotactic Body Radiation Therapy) as definitive therapy
3. Planned SoC SBRT as definitive treatment
4. World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) PS of 0, 1, or 2
5. Life expectancy of at least 12 weeks
6. Body weight >30 kg
7. Submission of available tumor tissue sample
8. Adequate organ and marrow function required
9. Patients with central or peripheral lesions are eligible
10. Staging studies must be done within 10 weeks before randomization
11. Pulmonary Function Testing within 12 weeks of randomization
12. Patients with a history of metachronus stage I/II (T1-T3N0M0) NSCLC treated definitively with surgery only or SBRT only >1 year prior to enrollment are eligible |
|
E.4 | Principal exclusion criteria |
1. Mixed small cell and non-small cell cancer
2. History of allogeneic organ transplantation
3. History of another primary malignancy with exceptions
4. History of active primary immunodeficiency
5. Any unresolved toxicity National Cancer Institute (NCI) CTCAE Grade ≥2 from
SBRT (Stereotactic Body Radiation Therapy) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
PFS in patients with subset of T1-T3N0 by BICR |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
On-study tumor assessments occur 8 weeks after randomization, then every 12 weeks through week 116, then every 16 weeks through 3 years after randomization, then every 6 months thereafter until objective disease progression. |
|
E.5.2 | Secondary end point(s) |
PFS in patients with T1-T3N0 NSCLC
OS in patients with subset of T1-T3N0 NSCLC
OS in patients with T1 to T3N0M0 NSCLC
Lung cancer mortality
PFS24, TTP, and TTDM using BICR assessments according to RECIST 1.1
PFS2 using local assessment
Concentration of durvalumab in blood
Presence of ADA for durvalumab
EORTC QLQ-C30: Change in symptoms, functioning, and global health status/quality of life
Safety and tolerability: AEs, physical examinations, vital signs, electrocardiograms, and laboratory findings |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
OS: from randomization until death due to any cause
Lung cancer mortality: time from randomization until death due to lung cancer
PFS24: 24 months
TTP: time from randomization until progression (excluding deaths)
TTDM: time from randomization until death or distant metastasis
PFS2: time from randomization to second progression (local assessment)
ADA: will be collected at Baseline, at cycles 1, 8, 14, 26, 100 then months 3 and 6 after completed/discontinued study treatment
EORTC QLQ-C30: Screening, at Baseline, Week 2, 4, 6, 8, 12, 16 and 20 weeks after randomization, then every 8 weeks until 3 years after randomization, then every 6 months until PFS2
Safety and tolerability - from randomization until 3 months after treatment discontinuation |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Tolerability
Symptoms and health-related quality of life
Healthcare resource utilization |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 47 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Canada |
China |
France |
Germany |
Israel |
Italy |
Japan |
Korea, Republic of |
Netherlands |
Poland |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last expected visit/contact of the last patient undergoing the study (last subject last visit) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 7 |